Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.
Evans says the PREVAIL study is the first pre-chemotherapy study that has included patients with visceral metastases. Researchers found that patients with visceral metastases had significantly improved responses in the primary endpoints of radiographic progression-free survival and overall survival. Even though these patients did not fair as well as those in the non-visceral group, data was still statistically significant, Evans says.
Evans says this is important data because the median time to initiating chemotherapy for these patients is about 28 months — leaving patients ample time to receive treatments prior to chemotherapy even if they have other disease sites.
<<< View more from the 2014 AUA Annual Meeting